Its revenue grew 10.1% to ₹1.10 lakh crore from ₹99,926 crore in Q3FY24.

"The Indian travel and tourism sector is witnessing robust growth, reflecting a strong desire among travellers to explore new horizons. While Indian destinations continue to shine, many countries have made significant efforts to attract Indian travellers," Rajesh Magow, Group Chief Executive Officer of MakeMyTrip, said.

"Our strong performance this quarter reflects these macro trends, along with our focused execution and commitment to customer centricity," he added.

MakeMyTrip (MMT), a NASDAQ-listed online travel company, on Thursday reported a 12% jump in its net profit at $27.1 million for the quarter ended December 31, 2024, on the back of higher gross bookings. The company's net profit stood at $24.2 million in the year-ago period (Q3 FY24).

According to International Financial Reporting Standards (IFRS), MMT's revenue stood at $267.4 million for the reporting quarter, up 26.2% as compared with $214.2 million reported in Q3 FY24.

In the corresponding period last year, its revenue from India stood at ₹1,180 crore.

In the corresponding period last year, its revenue from the Europe market stood at ₹497 crore.

In the corresponding period last year, its revenue from the North American market stood at ₹3,349.2 crore.

• Dr. Reddy's consolidated Nicotine Replacement Therapy ('NRT') financials in this quarter. Integration of the NRT business progressing as per plan.
• It entered ntered into a voluntary licensing agreement with Gilead Sciences to manufacture and commercialise HIV treatment drug, Lenacapavir, in 120+ countries.
• It got promising results in Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma announced by its subsidiary, Aurigene Oncology Limited.
• Alvotech, its US and Europe partner completed filing for Denosumab biosimilar.
• It launched Toripalimab, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma in India.
• It launched Elobixibat, a first-in-class drug to treat chronic constipation, under the brand name BixiBat®, in India.

"The company's third-quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter," Syngene International MD and CEO, Jonathan Hunt said.

"Revenue growth during the quarter was impacted due to a delay in the renewal of a B2B deal. Renewal discussions are underway. Expect performance improvement momentum to sustain with growth providing some operating leverage," ZEEL said in an exchange filing.

Its total expenses stood at ₹1,734.7 crore in Q3FY25, down 10.17% from ₹1,931.1 crore in the corresponding period last year.

"...Zee Network Share Up 40 bps YoY, driven by Hindi Movies & Marathi," it said in a filing.

Shares of UltraTech Cement are trading at ₹11,296.65, up 5.64% on the NSE despite its Q3 net profit dropping 17% to ₹1,473.5 crore.

Shares of Senores Pharmaceuticals galloped 8.26% to ₹539.70 on the NSE before its Q3 result announcement on Thursday, January 23.

Shares of Zee Entertainment Enterprises Ltd soared 2.35% to touch ₹120.73 on the NSE. The media house will announce its Q3 results today.

Shares of Adani Energy Solution were trading in the red at ₹795.45, down 0.92% on the NSE today ahead of its Q3 earnings announcement.

Coforge's board approved an interim dividend of ₹19 per share. The record date has been fixed as Thursday, January 30, 2025.

Coforge signs a $17.85 million deal to acquire 100% stake in Xceltrait Inc.

“A 8.4% sequential cc growth, a 40.3% cc YoY growth (in USD million) in a seasonally weak quarter, four large deals in that same quarter, a concurrent and material sequential expansion of 122 bps in margins, a Cigniti business that has already touched an EBITDA margin of 17.3%, a large deals pipeline that is looking very robust and finally an ever strengthening next twelve month signed order book which now is 40% higher YoY gives us confidence that the coming year shall once again see robust and sustained growth.” said Sudhir Singh, Chief Executive Officer and Executive Director of Coforge Ltd.

Shares of Mankind Pharma were trading at ₹2,545.70, up 1.16% on the NSE on Wednesday, January 23. The company will release its Q3 results today.

Shares of Persistent Systems climb 8.21% to trade at ₹466.85 apiece on the NSE, a day after the company reported its December quarter results.

Shares of UltraTech Cement were trading at ₹10,863.50 apiece, up 1.59% ahead of its Q2 result announcement.

Originally, the company was going to release its Q3 report card on Tuesday, January 21. Howerver, it postponed the announcement to January 23.

Shares of pharmaceutical major Dr Reddy's Laboratories were trading at ₹1,287.35 on the NSE, reflecting a decline of 0.69%.

Ahead of the earnings announcement, shares of Adani Green Energy were trading 0.89% lower at 1,033.50 apiece on the NSE.